Papel de las células madre tumorales en la respuesta a nuevos fármacos selectivos frente a cáncer de colon y mama

Abstract

Cancer is one of the most important diseases all over the world. Cancer Stem Cells (CSCs) plays a critical role on tumorigenesis and resistance against conventional therapies resulting on appearance of recurrence and metastasis. Nowadays, there is an increasing interest in developing targeted therapies against both tumoral and CSC. Our objective was to select, from a set of newly synthesized drugs, the compound with more antitumor activity in differentiated and CSCs of breast and colon cancer. AII compounds have an antitumor effect but Bozepinib, showed a powerfull and selective antiproliferative activity against tumoral and CSC in breast and colon cancer by inhibiting tumorogenic and CSC related pathways. In our in vivo study, high doses of Bozepinib do not induce chronic or acute toxicity and exhibits potent antitumor activity. These results indicate the effectiveness of Bozepinib as harmacological agent against CSCs that may improve the response of patients with this pathology.